Clinical significance of serum hepatocyte growth factor and epidermal growth factor gene somatic mutations in patients with non-squamous non-small cell lung cancer receiving gefitinib or erlotinib

Katsuhiro Masago, Yosuke Togashi, Shiro Fujita, Yuichi Sakamori, Chiyuki Okuda, Young Hak Kim, Tadashi Mio, Michiaki Mishima

Research output: Contribution to journalArticlepeer-review

17 Citations (Scopus)

Abstract

A study of patients with advanced non-squamous non-small cell lung cancer (NSCLC) evaluated epidermal growth factor receptor (EGFR) mutation status and serum hepatocyte growth factor (HGF) for their associations with response to gefitinib therapy and prognostic impact. An enzyme-linked immunosorbent assay was used to determine levels of HGF in serum from 96 Japanese patients with advanced non-squamous NSCLC. The peptic nucleic acid-locked nucleic acid clamp method was used to determine their EGFR somatic mutation status. We evaluated the relationship between each independent clinicopathological variable and the response to gefitinib therapy and risk factors associated with prognosis. HGF-positive serum status (hazard ratio, 1.536; 95% confidence interval, 1.042-2.400; P = 0.0295) had a significant and independent negative effect on progression-free survival among patients with wild-type EGFR. We demonstrate that having HGF-positive serum is predictive of a negative response to gefitinib therapy in patients with advanced NSCLC who harbor wild-type EGFR.

Original languageEnglish
Pages (from-to)1614-1621
Number of pages8
JournalMedical Oncology
Volume29
Issue number3
DOIs
Publication statusPublished - Sep 2012
Externally publishedYes

Keywords

  • Epidermal growth factor receptor
  • Gefitinib
  • Hepatocyte growth factor
  • Non-small cell lung cancer
  • Somatic mutation

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Clinical significance of serum hepatocyte growth factor and epidermal growth factor gene somatic mutations in patients with non-squamous non-small cell lung cancer receiving gefitinib or erlotinib'. Together they form a unique fingerprint.

Cite this